Medrx Co., Ltd. (JP:4586)

:4586

4586

Medrx Co., Ltd.

RESEARCH TOOLSreports

Medrx Co., Ltd. (4586) Price & Analysis

Compare

0 Followers

4586 Stock Chart & Stats

¥113.00

¥2.00(2.50%)

At close: Jan 08 4:00 PM EST

¥113.00

¥2.00(2.50%)

Day’s Range― - ―

52-Week Range¥55.00 - ¥225.00

Previous CloseN/A

Volume596.00K

Average Volume (3M)2.57M

Market Cap

¥6.95B

Enterprise Value¥4.95B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.42

Next Earnings

May 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.60

Shares Outstanding59,365,100

10 Day Avg. Volume1,116,360

30 Day Avg. Volume2,574,156

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (no Debt)Medrx’s zero-debt position from 2021–2025 materially reduces solvency risk and interest burdens, giving management durable financial flexibility. Over a 2–6 month horizon this supports continued R&D and partnering negotiations without immediate creditor pressure, aiding strategic optionality.

Very High Gross MarginsSustained gross margins near 85–90% signal structural profitability at the product level tied to its proprietary transdermal technology. High product-level economics support scalable licensing, strong per-unit contribution and long-term margin resilience if fixed operating costs are controlled.

Sharp 2025 Revenue ReboundA large revenue rebound in 2025 suggests recent commercialization or partnership progress that materially increased top-line throughput. For the medium term this provides evidence of commercial traction that can translate into recurring licensing, milestone and supply revenues if sustained.

Bears Say

Persistent Cash BurnThe company generates negative operating and free cash flow annually, indicating it is not self-funding operations. Over months this necessitates external financing or equity raises, which can dilute shareholders, constrain discretionary investment and raise execution risk for product launches.

Severe And Worsening Net LossesDeepening net losses and a collapsing net margin reflect operating costs far outpacing revenue growth. Persisting at this scale will erode equity, reduce reinvestment capacity and hinder the company’s ability to convert product-level margins into positive net profitability in the medium term.

Highly Volatile Revenue / Small ScaleRevenue volatility and a relatively small operational base make results sensitive to timing of partnerships, milestones and single-product sales. This structural variability complicates planning, risks uneven cash flow, and makes margins and capital needs less predictable across 2–6 months.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥55.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥6.95B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 42 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.6.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 59,365,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥2.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.885%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.